Fuse Science Appoints Biotech CEO, PhD and Capital Markets Expert to Independent Board Seat

MIAMI LAKES, Fla., March 13, 2012 /PRNewswire/ -- Fuse Science Inc. (OTCQB: DROP), (www.fusescience.com), announced today that it has appointed Dr. Doug Armstrong, to an Independent Voting Director position on its board. This move further expands the depth and resources available to Fuse Science to support its long term success and in the full execution of its business strategy.

R. Douglas Armstrong, Ph.D., has over 25 years of life science industry business and finance experience, with emphasis on early stage and emerging growth life science companies. Dr. Armstrong previously served as the Chief Executive Officer of TyraTech and Aastrom Biosciences (where he was also Chairman of the board), leading both through initial public offerings, and has been a member of the board for several other healthcare companies. He is currently a member of the senior management of Tekesta Capital Partners, a division of WestPark Capital, Inc., and is also a founding partner and president of Auxol Capital LLC, life science investment fund.

"Fuse Science offers a unique business proposition in the life sciences field and I am thrilled to be joining the team," added Dr. Armstrong. "I believe my operational expertise in the biotech industry and, in particular, the public capital markets, can help guide the company through this important stage of its lifecycle and beyond."

"I am extremely excited to welcome Dr. Armstrong to our Powered By Fuse team," said Brian Tuffin, Fuse Science's Chief Executive Officer. "There is no substitute for quality of talent and Dr. Armstrong brings a wealth of experience and capabilities that will have an immediate impact on the company's progress."

Dr. Armstrong also previously served as a staff scientist for The Burnham Institute (La Jolla Cancer Research Institute) and Assistant Professor, Department of Pharmacology and Cancer Research Institute at the University of California. He holds a Ph.D. degree in Pharmacology from the Medical College of Virginia, and a BA degree in Chemistry from the University of Richmond.

About Fuse Science Inc.
Fuse Science Inc. (OTCQB: DROP), is an innovative consumer products holding company based in Miami Lakes, Florida. Fuse Science is the developer of new, patent-pending technologies poised to redefine how consumers receive energy, medicines, vitamins and minerals. The company has successfully developed and maintains the rights to sublingual and transdermal delivery systems for bioactive agents that can now, for the first time, effectively encapsulate and charge many varying molecules in order to produce complete product formulations which can bypass the gastrointestinal tract and enter the blood stream directly - all in a concentrated "DROP" form that is simply applied under the tongue. The Fuse Science technology is designed to accelerate conveyance of medicines or nutrients relative to traditional pills and liquids and can enhance how consumers receive these products. Information about Fuse Science is available online at www.fusescience.com and www.poweredbyfuse.com or by calling 305-503-FUSE (3873).

Safe Harbor Statement: Certain statements and information included in this release may constitute "forward-looking statements" as defined in the Federal Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied in such statements. Additional discussion of factors that could cause actual results to differ materially from management's projections, estimates and expectations is contained in the Company's SEC filings. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by federal securities laws.

SOURCE Fuse Science Inc.

Back to news